Xintela AB (publ) (XINT.ST)
SEK 0.37
(1.36%)
SEK 0.37
(1.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -54.08 Million SEK | 18.32% |
| 2022 | -66.21 Million SEK | -12.36% |
| 2021 | -58.93 Million SEK | -11.35% |
| 2020 | -52.92 Million SEK | -21.53% |
| 2019 | -43.54 Million SEK | -65.75% |
| 2018 | -26.27 Million SEK | -19.73% |
| 2017 | -21.94 Million SEK | -21.51% |
| 2016 | -18.06 Million SEK | -56.24% |
| 2015 | -11.55 Million SEK | -284.32% |
| 2014 | -3 Million SEK | -32.0% |
| 2013 | -2.27 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -10.99 Million SEK | 6.02% |
| 2024 Q2 | -9.99 Million SEK | 9.16% |
| 2023 Q1 | -16.47 Million SEK | -0.26% |
| 2023 Q4 | -11.7 Million SEK | -43.72% |
| 2023 FY | -54.08 Million SEK | 18.32% |
| 2023 Q3 | -8.14 Million SEK | 55.75% |
| 2023 Q2 | -18.4 Million SEK | -11.66% |
| 2022 Q4 | -16.43 Million SEK | 0.38% |
| 2022 Q3 | -16.49 Million SEK | 19.32% |
| 2022 Q2 | -20.45 Million SEK | -21.89% |
| 2022 Q1 | -16.77 Million SEK | 37.02% |
| 2022 FY | -66.21 Million SEK | -12.36% |
| 2021 FY | -58.93 Million SEK | -11.35% |
| 2021 Q4 | -26.64 Million SEK | -144.2% |
| 2021 Q1 | -9.04 Million SEK | 64.29% |
| 2021 Q3 | -10.91 Million SEK | 7.52% |
| 2021 Q2 | -11.79 Million SEK | -30.41% |
| 2020 FY | -52.92 Million SEK | -21.53% |
| 2020 Q1 | -7.51 Million SEK | 51.33% |
| 2020 Q3 | -8.31 Million SEK | 8.5% |
| 2020 Q4 | -25.33 Million SEK | -204.69% |
| 2020 Q2 | -9.08 Million SEK | -20.85% |
| 2019 Q4 | -15.44 Million SEK | -94.06% |
| 2019 Q3 | -7.96 Million SEK | 25.31% |
| 2019 Q2 | -10.65 Million SEK | -12.66% |
| 2019 Q1 | -9.46 Million SEK | -8.83% |
| 2019 FY | -43.54 Million SEK | -65.75% |
| 2018 FY | -26.27 Million SEK | -19.73% |
| 2018 Q4 | -8.69 Million SEK | -98.43% |
| 2018 Q3 | -4.38 Million SEK | 18.46% |
| 2018 Q2 | -5.37 Million SEK | 31.35% |
| 2018 Q1 | -7.82 Million SEK | -17.95% |
| 2017 Q4 | -6.63 Million SEK | -35.87% |
| 2017 FY | -21.94 Million SEK | -21.51% |
| 2017 Q1 | -5.4 Million SEK | -121.05% |
| 2017 Q2 | -5.01 Million SEK | 7.27% |
| 2017 Q3 | -4.88 Million SEK | 2.63% |
| 2016 FY | -18.06 Million SEK | -56.24% |
| 2016 Q1 | -3.62 Million SEK | 26.68% |
| 2016 Q4 | -2.44 Million SEK | 19.08% |
| 2016 Q3 | -3.02 Million SEK | 42.27% |
| 2016 Q2 | -5.23 Million SEK | -44.42% |
| 2015 Q3 | -1.81 Million SEK | 34.06% |
| 2015 Q2 | -2.75 Million SEK | -14.67% |
| 2015 Q1 | -2.39 Million SEK | 0.0% |
| 2015 FY | -11.55 Million SEK | -284.32% |
| 2015 Q4 | -4.94 Million SEK | -172.71% |
| 2014 FY | -3 Million SEK | -32.0% |
| 2013 FY | -2.27 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -228.174% |
| Amniotics AB (publ) | -30.87 Million SEK | -75.196% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -321.601% |
| BioArctic AB (publ) | 229.24 Million SEK | 123.591% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 88.399% |
| Genovis AB (publ.) | 61.5 Million SEK | 187.94% |
| LIDDS AB (publ) | -40.2 Million SEK | -34.515% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 544.433% |
| OncoZenge AB (publ) | -15.9 Million SEK | -240.102% |
| Saniona AB (publ) | -95.81 Million SEK | 43.552% |
| Simris Alg AB (publ) | -37.3 Million SEK | -44.975% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 82.607% |
| AcouSort AB (publ) | -17.08 Million SEK | -216.478% |
| Active Biotech AB (publ) | -45.8 Million SEK | -18.085% |
| Camurus AB (publ) | 431.44 Million SEK | 112.535% |
| Cantargia AB (publ) | -280.02 Million SEK | 80.687% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -156.427% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 52.275% |
| Mendus AB (publ) | -101.61 Million SEK | 46.779% |
| Kancera AB (publ) | -64.88 Million SEK | 16.653% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 1104.14% |
| Lipum AB (publ) | -37.17 Million SEK | -45.47% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -345.935% |
| NextCell Pharma AB | -41.95 Million SEK | -28.892% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 86.067% |
| Ziccum AB (publ) | -21.41 Million SEK | -152.583% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -229.815% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -202.19% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -45.89% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 69.898% |
| CombiGene AB (publ) | -35.66 Million SEK | -51.64% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 64.384% |
| Intervacc AB (publ) | -102.85 Million SEK | 47.417% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 78.244% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -12247.717% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -227.319% |
| Corline Biomedical AB | -1.8 Million SEK | -2889.663% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 69.589% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 4.819% |
| Aptahem AB (publ) | -11.11 Million SEK | -386.67% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 56.054% |
| Fluicell AB (publ) | -26.55 Million SEK | -103.672% |
| Biovica International AB (publ) | -124.82 Million SEK | 56.672% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -28.089% |
| Abliva AB (publ) | -95.5 Million SEK | 43.374% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 83.456% |
| 2cureX AB (publ) | -32.51 Million SEK | -66.317% |
| I-Tech AB | 20.2 Million SEK | 367.698% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 93.497% |
| Cyxone AB (publ) | -22.98 Million SEK | -135.256% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 40.829% |
| Biosergen AB | -27.03 Million SEK | -100.033% |
| Nanologica AB (publ) | -75.15 Million SEK | 28.04% |
| SynAct Pharma AB | -215.81 Million SEK | 74.94% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -22.765% |
| BioInvent International AB (publ) | -330.3 Million SEK | 83.626% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -127.843% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 78.29% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -444.642% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 50.513% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -363.119% |